Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | GRK5 | P34947 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL513377 | 0.94 | ALDH1A1 (0.41) | ADORA2AADORA2BHTR2CALDH1A1BRD4 | |
| SCHEMBL20157289 | 0.77 | MAPT (0.41) | ADORA2AADORA2BHTR2CALDH1A1BRD4 | |
| SCHEMBL394010 | 0.74 | MAPT (0.40) | ADORA2AADORA2BHTR2CBRD4MAPT | |
| SCHEMBL24376356 | 0.74 | MAPK8 (0.37) | HTR2CALDH1A1BRD4MAPTMAPK8 | |
| SCHEMBL13578901 | 0.74 | ALDH1A1 (0.41) | HTR2CALDH1A1BRD4CDK8 | |
| SCHEMBL12021767 | 0.74 | ALDH1A1 (0.55) | HTR2CALDH1A1BRD4 | |
| SCHEMBL3614856 | 0.72 | HTR3A (0.51) | ALDH1A1BRD4HTR3ACREBBPMAPT | |
| SCHEMBL13578883 | 0.72 | KMT2A (0.55) | ADORA2AADORA2BHTR2CALDH1A1PIM3 | |
| SCHEMBL513376 | 0.71 | KDM4E (0.35) | ADORA2AADORA2BHTR2CBRD4PIM3 | |
| SCHEMBL21093429 | 0.71 | LMNA (0.44) | ADORA2AADORA2BALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4593598-A1 | STORAGE-STABLE COMPOSITIONS INCLUDING BIXLOZONE AND BEFLUBUTAMID | FMC Corporation (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-114555563-B | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-114144409-B | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118265781-A | Herbicide resistance | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118108674-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118084803-A | Substituted pyridazinones as herbicides | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113271779-B | Herbicidal composition | 先正达参股股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024073019-A1 | STORAGE-STABLE COMPOSITIONS INCLUDING BIXLOZONE AND B EFLUB UT AMID | FMC CORPORATION (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-111566094-B | herbicidal compounds | 先正达参股股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-111018790-B | Pyridazinone herbicides | FMC公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ADORA2A 2165/4885ADORA2B 2267/4885HTR2C 3761/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | ADORA2A 4330/4885ADORA2B 4643/4885HTR2C 4280/4885 |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ADORA2A 2076/4885ADORA2B 2129/4885HTR2C 3846/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ADORA2A 2200/4885ADORA2B 2350/4885HTR2C 4039/4885 |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ADORA2A 2065/4885ADORA2B 2126/4885HTR2C 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.